ArticleMycopathologia2026
Clinical and Microbiological Characteristics of Sterile-Site Saccharomyces cerevisiae Infections in a Tertiary-Care Centre.
Article in Mycopathologia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Saccharomyces cerevisiae has increasingly been recognized as an opportunistic pathogen. Sterile-site infections remain rare but are associated with substantial morbidity and mortality, especially in critically ill patients. This study aimed to characterize the epidemiological, clinical, and microbiological characteristics of sterile-site S. cerevisiae infections. We performed a retrospective analysis of all patients with S. cerevisiae isolated from sterile body sites between January 2019 and December 2025. Demographic data, underlying conditions, probiotic exposure, antifungal therapy, and outcomes were collected, and antifungal susceptibility testing was performed. Among 196 patients with S. cerevisiae isolates, 30 (15%) had sterile-site infections. The mean age was 47.2 years, and 23% were paediatric cases. Bloodstream infections were the most common source (n = 7, 23%), followed by intra-abdominal abscess aspirates and drained intra-abdominal wounds (each n = 5, 17%). Intensive care unit (ICU) admission occurred in 33%, prior gastrointestinal surgery in 63%, central venous catheter usage in all fatal cases, and prior probiotic exposure in 30%. Overall, 30-day mortality was 27%. In multivariable analysis, increasing age (adjusted OR 1.11 per year, 95% CI 1.02-1.37; p = 0.008) and ICU admission (adjusted OR 10.09, 95% CI 1.23-259.6; p = 0.03) were independent predictors of mortality. Fluconazole showed variable activity, whereas amphotericin B and echinocandins demonstrated low minimal inhibitory concentrations. Rare sterile-site S. cerevisiae infections are associated with high mortality related to host factors such as age and critical illness, supporting cautious probiotic use and first-line amphotericin B or echinocandins.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.